Sequential molecular and cellular events during neoplastic progression: A mouse syngeneic ovarian cancer model

Neoplasia

Volumn 7, Issue 10, 2005, Pages 944-956

  Roberts, Paul C ^a   Mottillo, Emilio P ^a   Baxa, Andrea C ^a   Heng, Henry H Q ^a   Doyon Reale, Nicole ^a   Gregoire, Lucie ^a   Lancaster, Wayne D ^a   Rabah, Raja ^a   Schmelz, Eva M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; E cadherin; Epigenetic silencing; Ovarian cancer; Promoter methylation

Indexed keywords

ACTIN; CONNEXIN 43; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN; CADHERIN; COLLAGEN; LAMININ; MATRIGEL; MESSENGER RNA; PROTEOGLYCAN;

ANEUPLOIDY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FOCAL ADHESION; GENE SILENCING; IN VIVO STUDY; METHYLATION; MONOLAYER CULTURE; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CELL ADHESION; CELL CULTURE; CHEMISTRY; CYTOSKELETON; DISEASE COURSE; DISEASE MODEL; DNA METHYLATION; DOWN REGULATION; DRUG COMBINATION; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC EPIGENESIS; METABOLISM; MITOSIS; NEOPLASM; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TEMPERATURE; TUMOR CELL LINE; WESTERN BLOTTING;

ACTINS; ANIMALS; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CONNEXIN 43; CYTOSKELETON; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; DRUG COMBINATIONS; EPIGENESIS, GENETIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE SILENCING; LAMININ; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; MITOSIS; NEOPLASMS; OVARIAN NEOPLASMS; PHENOTYPE; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; TEMPERATURE;

EID: 33644878654     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05358     Document Type: Article

References (53)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, and Thun MJ (2004). Cancer statistics, 2004. CA Cancer J Clin 54 (1), 8-29.
2. Auersperg N, Ota T, and Mitchell GW (2002). Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer 12 (6), 691-703.
3. Sundfeldt K (2003). Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol 202 (1-2), 89-96.
4. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et al. (2002). Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62 (16), 4722-4729.
5. Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, and Berchuck A (1993). Cell growth regulation in epithelial ovarian cancer. Cancer 71 (Suppl 4), 1597-1601.
6. Cruet S, Salamanca C, Mitchell GW, and Auersperg N (1999). alphav-beta3 and vitronectin expression by normal ovarian surface epithelial cells: role in cell adhesion and cell proliferation. Gynecol Oncol 75 (2), 254-260.
7. Auersperg N, Wong AS, Choi KC, Kang SK, and Leung PC (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22 (2), 255-288.
8. Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2 (6), 442-454.
9. Chipman JK, Mally A, and Edwards GO (2003). Disruption of gap junctions in toxicity and carcinogenicity. Toxicol Sci 71 (2), 146-153.
10. Auersperg N, Edelson MI, Mok SC, Johnson SW, and Hamilton TC (1998). The biology of ovarian cancer. Semin Oncol 25 (3), 281-304.
11. Patel IS, Madan P, Getsios S, Bertrand MA, and MacCalman CD (2003). Cadherin switching in ovarian cancer progression. Int J Cancer 106 (2), 172-177.
12. Davies BR, Worsley SD, and Ponder BA (1998). Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32 (1), 69-80.
13. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson PO, Enerback S, and Hedin L (1997). E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 74 (3), 275-280.
14. Peralta Soler A, Knudsen KA, Tecson-Miguel A, McBrearty FX, Han AC, and Salazar H (1997). Expression of E-cadherin and N-cadherin in surface epithelial-stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors. Hum Pathol 28 (6), 734-739.
15. Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, and Potet F (1997). Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28 (8), 922-928.
16. Risinger JI, Berchuck A, Kohler MF, and Boyd J (1994). Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 7 (1), 98-102.
17. Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, et al. (2002). CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 34 (4), 187-198.
18. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, and Baylin SB (1995). E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55 (22), 5195-5199.
19. Hanna EA, Umhauer S, Roshong SL, Piechocki MP, Fernstrom MJ, Fanning JD, and Ruch RJ (1999). Gap junctional intercellular communication and connexin43 expression in human ovarian surface epithelial cells and ovarian carcinomas in vivo and in vitro. Carcinogenesis 20 (7), 1369-1373.
20. Nishimura M, Saito T, Yamasaki H, and Kudo R (2003). Suppression of gap junctional intercellular communication via 5′ CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells. Carcinogenesis 24 (10), 1615-1623.
21. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, and Terranova PF (2000). Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21 (4), 585-591.
22. Heng HH, Liu G, Lu W, Bremer S, Ye CJ, Hughes M, and Moens P (2001). Spectral karyotyping (SKY) of mouse meiotic chromosomes. Genome 44 (2), 293-298.
23. Ye CJ, Lu W, Liu G, Bremer SW, Wang YA, Moens P, Hughes M, Krawetz SA, and Heng HH (2001). The combination of SKY and specific loci detection with FISH or immunostaining. Cytogenet Cell Genet 93 (3-4), 195-202.
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, and Baylin SB (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (18), 9821-9826.
25. Li LC and Dahiya R (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18 (11), 1427-1431.
26. Gregoire L, Rabah R, Schmelz EM, Munkarah A, Roberts PC, and Lancaster WD (2001). Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin Cancer Res 7 (12), 4280-4287.
27. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, and Hendrix MJ (2004). Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190 (4), 899-909.
28. Jones PA and Baylin SB (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (6), 415-428.
29. Maines-Bandiera SL, Kruk PA, and Auersperg N (1992). Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 167 (3), 729-735.
30. Nitta M, Katabuchi H, Ohtake H, Tashiro H, Yamaizumi M, and Okamura H (2001). Characterization and tumorigenicity of human ovarian surface epithelial cells immortalized by SV40 large T antigen. Gynecol Oncol 81 (1), 10-17.
31. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, et al. (2004). A genetically defined model for human ovarian cancer. Cancer Res 64 (5), 1655-1663.
32. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, and Nikitin AY (2003). Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63 (13), 3459-3463.
33. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, and Hamilton TC (2003). Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63 (6), 1389-1397.
34. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, and Hamilton TC (1992). Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 84 (8), 592-601.
35. Testa JR, Getts LA, Salazar H, Liu Z, Handel LM, Godwin AK, and Hamilton TC (1994). Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 54 (10), 2778-2784.
36. Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, et al. (2004). Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res 64 (22), 8177-8183.
37. Malaguarnera L, Ferlito L, Di Mauro S, Imbesi RM, Scalia G, and Malaguarnera M (2001). Immunosenescence and cancer: a review. Arch Gerontol Geriatr 32 (2), 77-93.
38. Kusyk CJ, Seski JC, Medlin WV, and Edwards CL (1981). Progressive chromosome changes associated with different sites of one ovarian carcinoma. J Natl Cancer Inst 66 (6), 1021-1025.
39. Maines-Bandiera SL and Auersperg N (1997). Increased E-cadherin expression in ovarian surface epithelium: an early step in metaplasia and dysplasia? Int J Gynecol Pathol 16 (3), 250-255.
40. MacCalman CD, Farookhi R, and Blaschuk OW (1994). Estradiol regulates E-cadherin mRNA levels in the surface epithelium of the mouse ovary. Clin Exp Metastasis 12 (4), 276-282.
41. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T, and Konishi I (2003). Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163 (4), 1437-1447.
42. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A, and Roskelley CD (1999). E-cadherin induces mesenchymal-to- epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96 (11), 6249-6254.
43. Hirohashi S and Kanai Y (2003). Cell adhesion system and human cancer morphogenesis. Cancer Sci 94 (7), 575-581.
44. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, et al. (2002). Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8 (7), 2246-2252.
45. Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH, and Nephew KP (2001). DNA methylation and ovarian cancer: I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 82 (2), 261-268.
46. Ahluwalia A, Hurteau JA, Bigsby RM, and Nephew KP (2001). DNA methylation in ovarian cancer: II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 82 (2), 299-304.
47. Zhu Y, Maric J, Nilsson M, Brannstrom M, Janson PO, and Sundfeldt K (2004). Formation and barrier function of tight junctions in human ovarian surface epithelium. Biol Reprod 71 (1), 53-59.
48. Yamasaki H, Omori Y, Zaidan-Dagli ML, Mironov N, Mesnil M, and Krutovskikh V (1999). Genetic and epigenetic changes of intercellular communication genes during multistage carcinogenesis. Cancer Detect Prev 23 (4), 273-279.
49. Umhauer S, Ruch RJ, and Fanning J (2000). Gap junctional intercellular communication and connexin 43 expression in ovarian carcinoma. Am J Obstet Gynecol 182 (5), 999-1000.
50. Mehta PP, Perez-Stable C, Nadji M, Mian M, Asotra K, and Roos BA (1999). Suppression of human prostate cancer cell growth by forced expression of connexin genes. Dev Genet 24 (1-2), 91-110.
51. Fernstrom MJ, Koffler LD, Abou-Rjaily G, Boucher PD, Shewach DS, and Ruch RJ (2002). Neoplastic reversal of human ovarian carcinoma cells transfected with connexin43. Exp Mol Pathol 73 (1), 54-60.
52. Esinduy CB, Chang CC, Trosko JE, and Ruch RJ (1995). In vitro growth inhibition of neoplastically transformed cells by non-transformed cells: requirement for gap junctional intercellular communication. Carcinogenesis 16 (4), 915-921.
53. Hernandez-Blazquez FJ, Joazeiro PP, Omori Y, and Yamasaki H (2001). Control of intracellular movement of connexins by E-cadherin in murine skin papilloma cells. Exp Cell Res 270 (2), 235-247.